ADRA1B抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Human lung cancer tissue, Primary antibody: P03771(ADRA1B Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P03771(ADRA1B Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gasrtic cancer tissue using P03771(ADRA1B Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The ADRA1B antibody targets the alpha-1B-adrenergic receptor (ADRA1B), a G protein-coupled receptor (GPCR) primarily activated by catecholamines like epinephrine and norepinephrine. ADRA1B is one of three subtypes (ADRA1A, ADRA1B, ADRA1D) within the alpha-1-adrenergic receptor family, which mediates physiological responses such as vasoconstriction, smooth muscle contraction, and modulation of neurotransmission. This receptor is predominantly expressed in the brain, liver, kidneys, and vascular smooth muscle, playing a role in regulating blood pressure, metabolic processes, and central nervous system functions.

ADRA1B antibodies are essential tools for studying receptor localization, expression levels, and signaling mechanisms in both normal and pathological conditions. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate ADRA1B's involvement in diseases such as hypertension, benign prostatic hyperplasia, and neurological disorders. Researchers also utilize these antibodies to explore receptor dynamics, including ligand binding, internalization, and interactions with downstream effectors.

Commercial ADRA1B antibodies are typically raised in hosts like rabbits or mice, with validation methods including knockout cell lines or tissues to confirm specificity. Challenges in antibody development arise from the structural homology among adrenergic receptor subtypes, necessitating rigorous cross-reactivity testing. Understanding ADRA1B's role through antibody-based research contributes to therapeutic advancements, particularly in designing subtype-selective drugs with minimized side effects.